From USFDA
Zydus Cadila has received the final approval from USFDA to market Dexmedetomidine Hydrochloride Injection 200 mcg (base)/2 mL (100 mcg (base)/ mL single-dose vials. The drug is indicated for sedation of intuated and mechanically ventilated patients during treatment in an intensive care setting and for sedation of non-intubated patients prior to and /or during surgical and other procedures. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content